ArticleClinical drug investigation2021

Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.

Huahua Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.